Recordati stock: Barclays lifts target for Recordati stock from EUR 55.00 to EUR 56.00

Published on 10/21/2026 at 17:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The next results are due November 10, 2026. Recordati stock costs EUR 53.00 on October 21, 2026, up 0.09 percent versus the Xetra close.

Analyst target and reporting date

Barclays raised its Recordati target from EUR 55.00 to EUR 56.00 on October 21, 2026.
Recordati is scheduled to release third-quarter 2026 results on November 10, 2026.
Recordati stock costs EUR 53.00 at Lang & Schwarz on October 21, 2026 at 5:36 p.m. CEST, 0.09 percent above the Xetra close of October 21, 2026, and 2.66 percent below its 52-week high.
First-half 2026 net sales were EUR 1,411.00 million, compared with a EUR 1,393.00 million forecast.

Flatlay mit Aktienzertifikat, ISIN-Karte, Tabletten und Stethoskop auf Holztisch — Recordati S.p.A. (IT0003828271) symbolisiert dieses Flatlay mit Aktienzertifikat, ISIN-Karte und typischen Pharma-Utensilien, Illustration mit AI erstellt.

Barclays maintained its Equalweight recommendation for Recordati and raised the price target from EUR 55.00 to EUR 56.00 on October 21, 2026, according to Teleborsa. The new target is 5.66 percent above the EUR 53.00 Lang & Schwarz price on October 21, 2026. Recordati was trading at EUR 53.00 at Lang & Schwarz on October 21, 2026 at 5:36 p.m. CEST, up 0.09 percent versus the Xetra close of October 21, 2026 at EUR 52.95.

Results date sets the next marker

Recordati's next reporting milestone is the third-quarter 2026 earnings release scheduled for November 10, 2026. The company is also scheduled to hold its earnings presentation on November 11, 2026, according to MarketScreener. The dates give investors a defined checkpoint after Barclays moved its target by EUR 1.00.

Stock stays below its yearly high

The Lang & Schwarz price of EUR 53.00 on October 21, 2026 at 5:36 p.m. CEST stood EUR 1.45 below Recordati's 52-week high of EUR 54.45 and EUR 9.24 above its 52-week low of EUR 43.76. The range and the price-to-earnings ratio of 22.25 come from the same October 21, 2026 market snapshot. Trading volume was 103,633 shares on that date, while market capitalization stood at EUR 10.8 billion.

First-half sales exceeded the forecast

Recordati's first-half 2026 net sales were EUR 1,411.00 million, compared with a EUR 1,393.00 million forecast. Its first-half EBITDA was EUR 540.00 million, against a EUR 528.00 million forecast, according to MarketScreener. Recordati describes itself as a pharmaceutical company serving common and rare diseases in around 150 countries, with more than 4,700 employees, according to its investor-relations page.

What does the target change mean?

Barclays' revised EUR 56.00 target sits above the live euro quotation, but the recommendation remains Equalweight. That combination keeps the analyst view measured while the November reporting date supplies the next company-specific event.

Price position and next dates

Recordati's quotation was 2.66 percent below its 52-week high on October 21, 2026, calculated from EUR 53.00 and EUR 54.45. The board meeting is scheduled for November 9, 2026, followed by the earnings release on November 10, 2026.

Recordati stock was trading at EUR 53.00 at Lang & Schwarz on October 21, 2026 at 5:36 p.m. CEST, 0.09 percent above the Xetra close of October 21, 2026 at EUR 52.95. The further course of trading is shown by the continuously updated real-time quote of Recordati stock.